Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG)

16 сентября 2026 г. обновлено: Sinovac Biotech Co., Ltd

A Phase IV, Randomized, Double-blind, Positive-controlled , Multicenter Clinical Trial to Evaluate the Immunogenicity and Safety of Influenza Vaccine (Split Virion) , Inactivated (Anflu®) in Pregnant Women

A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in pregnant women.

A total of 150 healthy pregnant women aged 18~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) , Inactivated (Anflu®) or Sanofi VAXIGRIP®, respectively.

Обзор исследования

Статус

Еще не набирают

Условия

Вмешательство/лечение

Подробное описание

A phase IV clinical trial of Influenza Vaccine (Split Virion), Inactivated (Anflu®) developed by Sinovac Biotech Co., Ltd will be conducted in Chinese pregnant women.

A total of 150 healthy pregnant women aged 18~45 years at 22 to 34 weeks (+6 days) of pregnancy will be enrolled.The trial is a randomized, double-blind, positive controlled study to evaluate the immunogenicity and safety of Influenza Vaccine (Split Virion) ,Inactivated (Anflu®) manufactured by Sinovac. The active control vaccine is VAXIGRIP® manufactured by Sanofi.

For immunogenicity assessment, blood samples will be collected from participants prior to vaccination, 28 days post-vaccination, and at the end of pregnancy (at delivery) to evaluate antibody levels in pregnant women following influenza vaccination. Additionally, the cord blood samples will be collected at delivery to assess transplacental antibody transfer to the fetus. Antibodies will be tested using the hemagglutination-inhibition (HI) assay.

For safety assessment, any immediate adverse events within 30 minutes after vaccine administration, solicited local and systemic adverse events within 7 days and unsolicited adverse events within 28 days will be collected. Serious adverse events will be collected from the time of informed consent signature until 3 months after delivery (or until 3 months after the event if pregnancy termination occurs). Pregnancy and neonatal outcomes will be collected by medical record review .

Тип исследования

Интервенционный

Регистрация (Оцененный)

150

Фаза

  • Фаза 4

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

  • Имя: Qi Hongbo
  • Номер телефона: 13808376116
  • Электронная почта: qihongbo@cqmu.edu.cn

Места учебы

  • Китай
      • Changsha, Китай
        • Hunan Provincial Maternal and Child Health Care Hospital
        • Контакт:
          • Tang Yabing
      • Chengdu, Китай
        • Chengdu Women's and Children's Central Hospital
        • Контакт:
          • Lai Fan
      • Chongqing, Китай
        • The First Affiliated Hospital of Chongqing Medical University
        • Контакт:
          • Qi Hongbo
      • Guangzhou, Китай
        • Nanfang Hospital, Southern Medical University
        • Контакт:
          • Huang Liping
      • Nanjing, Китай
        • Nanjing Drum Tower Hospita
        • Контакт:
          • Li Jie
      • Wuhan, Китай
        • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Контакт:
          • Feng Ling

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 45 лет (Взрослый)

Принимает здоровых добровольцев

Да

Полы, имеющие право на обучение

Женский

Описание

Inclusion Criteria:

  1. Healthy pregnant women aged 18 to 45 years (inclusive) with stable health status, at 22 to 34 weeks (+6 days) of gestation. Gestational age is determined based on early ultrasound examination, or based on the last menstrual period if early ultrasound is unavailable.
  2. Participants are able to understand and sign the informed consent form voluntarily;
  3. Participants are willing and able to adhere to visit schedules and maintain accessible contact throughout the study period;
  4. Participants should provide verifiable identification;
  5. Have a singleton pregnancy;
  6. Have normal non-invasive prenatal DNA test and systematic ultrasound results during the current pregnancy; normal amniocentesis results are required if the test has been performed.

Exclusion Criteria:

  1. Have a history of two or more preterm deliveries (delivery before 37 weeks of gestation), previous infants with low birth weight (birth weight <2500 g), or a history of neonatal asphyxia or neonatal neurological damage;
  2. Have a history of multiple unexplained spontaneous abortions;
  3. Have received any influenza vaccine or the influenza vaccine for the current influenza season within 6 months prior to enrollment, or plan to receive influenza vaccination during the study period.
  4. Have suffered from seasonal influenza within 6 months prior to enrollment.
  5. Have a history of Guillain-Barré syndrome within 6 weeks after previous influenza vaccination.
  6. Have allergic reactions or other severe adverse reactions to any influenza vaccine or its components.
  7. Have severe autoimmune diseases or immunodeficiency diseases (including but not limited to active systemic lupus erythematosus, rheumatoid arthritis, asplenia, functional asplenia, and HIV infection) and are judged unsuitable for vaccination by the investigator.
  8. Abnormal coagulation function (such as coagulation factor deficiency, coagulation disorders or platelet abnormalities).
  9. Have severe chronic diseases (including but not limited to cardiovascular diseases, partial liver diseases, renal diseases or malignant tumors) that may interfere with the study as judged by the investigator.
  10. Have a current or previous history of severe neurological diseases (epilepsy, convulsions) or psychiatric disorders, or have a family history of psychiatric disorders.
  11. Received corticosteroids (adult prednisone ≥20 mg/day or equivalent) or other immunosuppressants for ≥14 days, or cytotoxic therapy within 6 months prior to vaccination, or plan to receive such therapy during the study period.
  12. Received immunoglobulins or other blood products within 3 months prior to vaccination, or plan to receive such products during the study period.
  13. Received any vaccine within 28 days prior to study vaccination, or plan to receive any vaccine within 28 days after study vaccination.
  14. Have enrolled in other clinical trials of investigational drugs or vaccines during the follow-up period, or plan to receive investigational drugs or vaccines during the study period.
  15. Have acute diseases or acute exacerbation of chronic diseases within 7 days before vaccination.
  16. Have fever on the scheduled vaccination day with an axillary temperature ≥37.3 °C before vaccination.
  17. Have clinically significant abnormal laboratory findings as judged by the investigator, or meet any of the following laboratory criteria: a) White blood cell count >15.0×10^9/L; b) Neutrophil percentage >85%; c) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times the upper limit of normal (2×ULN); d) Total bilirubin >2 times the upper limit of normal (2×ULN).
  18. Any other factors which are unsuitable for participation in the clinical trial as judged by the investigator.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Профилактика
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Четырехместный

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Test Group

100 participants will receive one dose of vaccine (0.5 mL) of Sinovac Influenza Vaccine (Split Virion) Inactivated (Anflu®) . Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose
Биологический: Anflu®

Participants will receive one dose of Sinovac Anflu® .
Активный компаратор: Control Group

50 participants will receive one dose of vaccine (0.5 mL) of VAXIGRIP® manufactured by Sanofi. Route of administration is intramuscular injection at deltoid muscle of upper arm.Immunization schedule is 1 dose
Биологический: Vaxigrip®

Participants will receive one dose of Sanofi Vaxigrip®.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: 28 days after vaccination

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroconversion is defined as either a baseline HI titer <1:10 and a post-vaccination titer ≥1:40 or a baseline HI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HI antibody titer.
28 days after vaccination
Incidence of adverse reactions within 28 days after vaccination
Временное ограничение: 28 days after vaccination

Incidence of adverse reactions within 28 days after vaccination. Adverse reactions include solicited and unsolicited adverse reactions. Solicited local (injection site) symptoms: pain, swelling, erythema, induration, pruritus; Solicited systemic (non-injection site) symptoms: fever (axillary temperature), fatigue, myalgia, headache, hypersensitivity reaction.
28 days after vaccination

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
The seroprotection rates (SPRs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: 28 days after vaccination

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.
28 days after vaccination
The geometric mean titers (GMTs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: 28 days after vaccination

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.
28 days after vaccination
The geometric mean fold rises (GMFRs) of HI antibodies at day 28 ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: 28 days after vaccination

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Geometric mean of antibody fold-rise with two-sided 95% CI will be calculated , along with the geometric mean ratio and its corresponding two-sided 95% CI.
28 days after vaccination
The SCRs of HI antibodies at delivery, as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery , estimated to be 6-18 weeks after randomization.

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroconversion is defined as either a baseline HI titer <1:10 and a post-vaccination titer ≥1:40 or a baseline HI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HI antibody titer.
At the date of delivery , estimated to be 6-18 weeks after randomization.
The SPRs of HI antibodies at delivery ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery , estimated to be 6-18 weeks after randomization.

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.
At the date of delivery , estimated to be 6-18 weeks after randomization.
The GMTs of HI antibodies at delivery,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery , estimated to be 6-18 weeks after randomization.

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.
At the date of delivery , estimated to be 6-18 weeks after randomization.
The GMFRs of HI antibodies at delivery,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery , estimated to be 6-18 weeks after randomization.

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Geometric mean of antibody fold-rise with two-sided 95% CI will be calculated , along with the geometric mean ratio and its corresponding two-sided 95% CI.
At the date of delivery , estimated to be 6-18 weeks after randomization.
The SPRs of HI antibodies in cord blood at delivery ,as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery, estimated to be 6-18 weeks after randomization

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Seroprotection is defined as an HI titer ≥1: 40.
At the date of delivery, estimated to be 6-18 weeks after randomization
The GMTs of HI antibodies in cord blood at delivery, as measured by HAI assay for vaccine-matched influenza A and B
Временное ограничение: At the date of delivery, estimated to be 6-18 weeks after randomization

Influenza A included H1N1 and H3N2 and influenza B strains included Victoria-lineage. Log-transformed post-vaccination HI antibody titer will be the dependent variable, with treatment group as fixed effect and log-transformed pre-vaccination HI antibody titer as covariate. Least-squares mean differences with two-sided 95% CIs will be estimated and back-transformed via exponentiation to derive adjusted GMT ratios (experimental vs control) and corresponding two-sided 95% CIs.
At the date of delivery, estimated to be 6-18 weeks after randomization
Incidence of serious adverse events from vaccination through 3 months after delivery.
Временное ограничение: From vaccination to 3 months after delivery.

Serious adverse events within 3 months after delivery.
From vaccination to 3 months after delivery.
Pregnancy outcomes
Временное ограничение: At the date of delivery, estimated to be 6-18 weeks after randomization

Pregnancy outcomes: term birth, preterm birth, elective termination of pregnancy, fetal death, and gestational complications, etc.
At the date of delivery, estimated to be 6-18 weeks after randomization
Neonatal birth outcomes
Временное ограничение: 3 months after delivery

Birth outcomes: normal status, low birth weight, congenital malformations, neonatal NICU admission, and neonatal death, etc.
3 months after delivery

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Sinovac Biotech Co., Ltd

Следователи

  • Главный следователь: Qi Hongbo, First Affiliated Hospital of Chongqing Medical University

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Оцененный)

1 октября 2026 г.

Первичное завершение (Оцененный)

1 февраля 2027 г.

Завершение исследования (Оцененный)

1 апреля 2027 г.

Даты регистрации исследования

Первый отправленный

28 августа 2026 г.

Впервые представлено, что соответствует критериям контроля качества

16 сентября 2026 г.

Первый опубликованный (Действительный)

21 сентября 2026 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

21 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

16 сентября 2026 г.

Последняя проверка

1 августа 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • PRO-INF-4015

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться